eShowcase: Oracle Initiatives Focus on Drug Safety
Recent announcements streamline adverse event reporting
Recent announcements streamline adverse event reporting
Oracle (Redwood Shores, CA) announced Safety in a Capsule, an IT and service collaboration between Oracle, Tata Consultancy Services (TCS), and DrugLogic. The offering combines Oracle's Siebel Contact Center Integration Pack for Oracle's Adverse Event Reporting (AER) System, DrugLogic's signal detection solution QScan, and TCS' Knowledge Process Outsourcing services to monitor and analyze pre- and postmarketing AER data for increased drug safety.
The Siebel Contact Center Integration Pack for the Oracle AER passes customer, product complaint, and potential AER information from the contact center to automatically load event-related information into the Oracle AER system. This solution works to reduce duplicate data entry, conflict resolution, and reconciliation. It is part of the Oracle Application Integration Architecture.
Oracle, (800) 672-2531, www.oracle.com
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
